In little more than a decade, CRISPR/Cas9 has gone from an obscure bacterial immune mechanism to one of the most powerful tools in modern science. Capable of editing genes with unprecedented precision, it has opened doors to treating inherited diseases, engineering more resilient crops, and rethinking how we address global health challenges. But as with any powerful tool, it comes with trade-offs. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), combined with the Cas9 protein, acts like a pair of molecular scissors guided by RNA. Originally found in bacteria as a defense system against viruses, scientists have repurposed it for gene editing in more complex organisms. The simplicity of designing guide RNAs and the relatively low cost have made CRISPR widely accessible across the globe. Its ability to target specific DNA sequences allows for either disruption of faulty genes or insertion of correct ones. This has revolutionized research in genetics, molecular biology, and biomedical sciences. Perhaps the most significant success of CRISPR lies in its clinical applications. In late 2023, the United States and United Kingdom approved Casgevy—a CRISPR-based therapy for sickle cell disease and beta thalassemia. It edits a patient’s stem cells ex vivo, correcting the genetic mutation before reinfusion. Similarly, researchers at the Broad Institute and Harvard have developed new forms of gene editing known as base editors and prime editors, which allow for more precise changes without introducing double-strand breaks in DNA. These next-generation tools could further minimize the risk of off-target effects. In agriculture, CRISPR has been used to create crops resistant to pests, diseases, and extreme weather. In 2022, researchers in Japan edited rice genomes to improve drought tolerance and reduce fertilizer dependence—potentially helping in climate adaptation strategies. Despite its promise, CRISPR is far from flawless. One of the most pressing concerns is off-target mutations, where unintended regions of DNA are edited, potentially leading to harmful effects. Although newer variants of Cas9 (like SpCas9-HF and eSpCas9) have improved specificity, complete elimination of off-target activity remains a challenge. A 2025 study conducted by Swiss researchers at ETH Zurich revealed large unintended deletions and chromosomal rearrangements during genome editing in human cells. These findings have raised alarms within the scientific community, particularly regarding CRISPR’s use in therapeutic settings. Another hurdle is efficient and safe delivery of CRISPR components into human cells. Viral vectors like AAV (Adeno-Associated Virus) are common but can trigger immune responses.
“Advances in AI and CRISPR make precise editing techniques crucial, requiring careful oversight. CRISPR offers vast potential from medical cures to climate-resilient crops, urging shared responsibility in shaping human health and evolution.”
Non-viral delivery systemsare under development, yet scalability and safety remain open questions. CRISPR also finds itself at the center of global ethical debates. In 2018, a Chinese scientist, He Jiankui, announced the birth of the world’s first gene-edited babies. His actions were widely condemned and led to prison time, as well as urgent calls for stronger oversight of germline editing. The World Health Organization and National Academies of Sciences in the US have since issued guidelines, urging caution and prohibiting heritable genome editing until long-term safety and societal consensus are achieved. Countries like India. 1 have permitted somatic gene therapy under strict regulatory control, but germline editing remains off-limits. Regulatory bodies such as the Central Drugs Standard Control Organization (CDSCO) and Indian Council of Medical Research (ICMR) emphasize rigorous evaluation of all gene-editing trials. New tools are being developed to address CRISPR’s limitations. Base editors, which convert one DNA base to another without cutting the DNA, and prime editors, capable of inserting or correcting sequences with surgical precision, are being heralded as safer alternatives. These systems are especially promising in treating diseases caused by single-point mutations, such as certain forms of cystic fibrosis, Tay-Sachs, and inherited blindness. Another promising direction is RNA-targeting CRISPR, such as Cas13, which allows temporary edits at the RNA level—offering possibilities for reversible treatments and diagnostics, especially in cancer and viral infections. The journey of CRISPR is still in its early chapters. While it has delivered on many of its promises, especially in diagnostics, crop science, and ex vivo cell therapy, serious questions remain. Regulatory bodies worldwide must balance innovation with caution. Public engagement will be critical—ensuring that communities understand not just what CRISPR can do, but also what it should do. Scientific breakthroughs must go hand in hand with transparent governance, robust bioethics, and inclusive global dialogue. As technologies like AI intersect with CRISPR, designing safer gRNAs and optimizing editing outcomes will become even more precise—but also demand careful oversight. CRISPR has opened up possibilities once thought to belong only to science fiction. From curing inherited diseases to adapting crops for climate resilience, its potential is vast. But as its reach expands, so too must our collective responsibility. What began as a microbial curiosity may end up reshaping human health, food systems, and even evolution itself. The question isn’t just what we can edit—but what we should.
(The author a student of Bio-Technology at S P College Srinagar is a freelancer. The views, opinions and conclusions expressed in this article are those of the author and aren’t necessarily in accord with the views of “Kashmir Horizon”)
